Understanding how patient-derived cancer organoids respond to treatment in cholangiocarcinoma
Official title: Defining Therapeutic Sensitivity of Patient-Derived Cancer Organoids in Cholangiocarcinoma
Funded at Wm S. Middleton Memorial Veterans Hosp · NIH-11063125 · Data updated 2026-11-12
This study is looking at ways to create mini versions of your cancer to see how different treatments work, with the hope of finding better options for people with bile duct cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wm S. Middleton Memorial Veterans Hosp NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| NIH project number | 5IK2BX006146-02 |
| Project ID | NIH-11063125 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with cholangiocarcinoma who are seeking innovative treatment options.
✕Less likely to help
Patients with early-stage cholangiocarcinoma or those not seeking treatment may not benefit from this research.
What this research studies
This research focuses on developing and standardizing patient-derived organoid models for cholangiocarcinoma, a type of bile duct cancer. By studying these organoids, researchers aim to better understand how different treatments affect cancer cells, which could lead to more effective therapies. The approach involves using organoids that mimic the patient's cancer to test various drugs and identify the most effective treatment options. This personalized approach aims to improve outcomes for patients suffering from this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with cholangiocarcinoma.
How similar studies have gone: Previous research has shown success in using patient-derived organoids for other types of cancers, indicating potential for similar advancements in cholangiocarcinoma.
Where this research is happening
-
Wm S. Middleton Memorial Veterans Hosp
Madison, United States Active
Researchers
- Principal investigator: Kratz, Jeremy David — Wm S. Middleton Memorial Veterans Hosp
- Study coordinator: Kratz, Jeremy David
Related research
Other NIH-funded projects on the same topics.
-
A new mouse model to study intrahepatic cholangiocarcinoma and its immunotherapy
A new mouse model helps researchers understand intrahepatic cholangiocarcinoma and test immune-based treatments to improve outcomes.
-
Radiation plus a patient’s own immune cells to boost cholangiocarcinoma treatment
This project tests a therapy that combines precise radiation and the patient’s own dendritic cells with immune drugs to help fight intrahepatic cholangiocarcinoma in people who cannot have surgery.
-
Worldwide genetics of bile duct (cholangiocarcinoma)
Researchers are looking for genetic patterns that raise the risk of bile duct cancer in people from diverse regions worldwide.
-
MKK4 and Liver Regeneration after Major Liver Surgery
A study at Mayo Clinic will test a new drug, HRX215, to help people regrow liver tissue after major liver surgery for cancer.
-
New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer
This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.
-
Mutant IDH in bile duct cancer and its impact on immune response
A patient-facing look at how mutations in IDH1 drive bile duct cancer and how targeting this mutation could help immune cells fight the tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.